Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin vs Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir/Ribavirin in HCV Treatment Failure
NCT03549832Completed
- Sponsor
- Assiut University
- Start
- Jan 2018
- Primary completion
- Jan 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of sofosbuvir, simeprevir, daclatasvir, ombitasvir, paritaprevir and 2 more in Hepatitis C genotype 4 (HCV-4) (2 arms), sponsored by Assiut University. Primary endpoint: Sustained Virologic Response at 12 weeks. Started Jan 2018; status: completed.
02
Drugs
sofosbuvirsimeprevirdaclatasvirombitasvirparitaprevir
03
Conditions
Hepatitis C genotype 4 (HCV-4)
Beyond the preview
Go deeper on NCT03549832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03549832.